vb119
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 5, 2021 (NCT04652570)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05441826 | Phase 2 | May 3, 2022 | ValenzaBio, Inc. |
| NCT04652570 | Phase 1/Phase 2 (Phase 2) | May 5, 2021 | ValenzaBio, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ValenzaBio, Inc. | For profit | 2 | 2 | 1 | 2021 |
1 organizations
Page 1 / 1